Fundraising Fox
ClearNote Health
San Diego, US · Founded 2016 · Delaware corporation · 1 known investors
Find your way into ClearNote Health
Sign up to see every warm intro you have to ClearNote Health
- Paths you didn't know you had: your email and LinkedIn already hold routes to the ClearNote Health team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
ClearNote Health develops DNA-based blood tests (the Avantect line for pancreatic, ovarian, and multi-cancer detection) aimed at detecting cancer at early stages in patients at elevated risk. It also offers Virtuoso, an epigenomics platform that measures disease biology and therapy response from a blood draw for drug discovery and development.
Founders & leadership
DM
David MullarkeyExecutive
SL
Samuel LevyChief Executive OfficerSamuel Levy brings nearly 30 years of experience in healthcare, biotechnology, life sciences, genomics, and clinical diagnostics, with a background in business development and general management across cross-functional teams. He serves as Executive Officer of ClearNote Health, which develops DNA-based blood tests for early cancer detection and an epigenomics platform for drug discovery.
JM
Johan Mattias WestermanNamed on SEC filing
Board
JM
Johan Mattias WestmanBoard director
TN
Tina NovaBoard director
SQ
Stephen QuakeBoard director
Investors · 1
Also in the syndicate · 1
Mattias Westmanlead
Funding
SEC filings, press & company announcements$143.1M disclosed across 3 rounds · 2019–2026
- $52MSeries DMay 2026 · 4 sources
Mattias Westman (lead)
Source ↗
▶$21.8MraisedJun 2025 · 5 investors · BiotechnologyRule 506(b)
▶$21.8MraisedJun 2025 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Tina NovaDirector
- David MullarkeyExecutive Officer, Director
- Samuel LevyExecutive Officer
- Johan Mattias WestmanDirector
- Stephen QuakeDirector
- Offering amount
- $60.5M
- Amount sold
- $21.8M
- First sale
- May 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$69.3MraisedJun 2021 · 14 investors · BiotechnologyRule 506(b)
▶$69.3MraisedJun 2021 · 14 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Stephen QuakeDirector
- Tina NovaDirector
- Johan Mattias WestermanDirector
- Samuel LevyExecutive Officer
- Offering amount
- $71.6M
- Amount sold
- $69.3M
- First sale
- Mar 2019
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 5
ToperaAbbott's Lingo Glucose System is a continuous glucose monitoring device for non-insulin users aged 18+, designed to track glucose levels and support metabolic health decisions.
LabcorpLabCorp provides diagnostic testing services and clinical trial recruitment solutions that connect patient insights to drug development for healthcare providers.
Guardant HealthGuardant Health develops blood-based testing (liquid biopsy) for cancer detection and monitoring across all stages of the disease. The company serves oncologists, patients, and biopharmaceutical firms with FDA-approved tests for cancer screening, early-stage risk assessment, and treatment selection.
Exact SciencesExact Sciences develops molecular diagnostic tests for cancer screening and detection, including multitarget stool DNA testing for colorectal cancer and multigene assays for breast cancer recurrence. The company serves patients and healthcare providers in the cancer diagnostics field.
American Cancer Society (ACS)The American Cancer Society is a nonprofit organization that provides cancer research updates, screening and prevention guidance, and community engagement opportunities. It serves individuals seeking cancer information and those who want to support cancer research and patient advocacy efforts.
Companies working in the same space as ClearNote Health.
In the news
Frequently asked questions
- What does ClearNote Health do?
- ClearNote Health develops DNA-based blood tests (the Avantect line for pancreatic, ovarian, and multi-cancer detection) aimed at detecting cancer at early stages in patients at elevated risk. It also offers Virtuoso, an epigenomics platform that measures disease biology and therapy response from a blood draw for drug discovery and development.
- How much funding has ClearNote Health raised?
- ClearNote Health has disclosed $143.1M raised across 3 rounds.
- Where is ClearNote Health headquartered?
- ClearNote Health is headquartered in San Diego, US.